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Oxyntomodulin (Oxm) is an intestinal peptide that inhibits food intake and body weight in
rodents and humans. These studies used peptide analogs to study aspects of structure and
functionofOxm, and the sensitivity ofpartsof theOxmsequence todegradation.AnalogsofOxm
were synthesizedand studiedusing receptorbindinganddegradation studies in vitro. Their effects
onfood intakeandconditionedtasteavoidanceweremeasured invivo in rodents.Oxmbreakdown
by the enzyme dipeptidyl peptidase IV (DPPIV) was demonstrated in vitro and in vivo. In vitro
degradationwas reduced and in vivo bioactivity increased by inhibitors of DPPIV.Modifications to
the N terminus of Oxm modulated binding to the glucagon-like peptide (GLP)-1 receptor and
degradation by DPPIV. Modifications to the midsection of Oxm modulated binding to the GLP-1
receptor and degradation by neutral endopeptidase. These modifications also altered bioactivity
in vivo. The C-terminal octapeptide of Oxm was shown to contribute to the properties of Oxm in
vitro and in vivo but was not alone sufficient for the effects of the peptide. Elongation and
acylation of the C terminus of Oxm altered GLP-1 receptor binding and duration of action in vivo,
whichmay be due to changes in peptide clearance. AnOxm analogwas developedwith enhanced
pharmaceutical characteristics, with greater potency and longevity with respect to effects on food
intake. These studies suggest that Oxm is a potential target for antiobesity drug design.
(Endocrinology 150: 1712–1721, 2009)
Oxyntomodulin (Oxm) is an intestinal peptide from the pre-proglucagon family, which inhibits gastric acid secretion
(1–3) and inhibits food intake (4). Oxm can bind to and activate
the glucagon-like peptide (GLP)-1 receptor (4, 5), albeit rela-
tivelyweakly (6).Theanorectic effects ofOxmareblockedby the
GLP-1 receptor antagonist exendin (9–39) and are absent in the
GLP-1 receptor knockout mouse, suggesting that they are me-
diated by the GLP-1 receptor (7). However, it has been reported
that similar doses ofOxmandGLP-1 are required to inhibit food
intake to an equivalent degree, despite their differential affinity
for the GLP-1 receptor (8). There is evidence that Oxm acts
primarily in the hypothalamic arcuate nucleus, whereas GLP-1
acts principally via the brainstem (8), though other studies have
not found these differences (7). The effects ofOxmandGLP-1on
nausea (9–12) and energy expenditure (7, 12–14)may also differ
in both rodents and humans. However, whereas a receptor dis-
tinct from the GLP-1 receptor may mediate some Oxm effects
(13), this has not to date been convincingly demonstrated. Oxm
and GLP-1 may differ in terms of central nervous system pene-
tration or tissue-specific modification of receptor function but
appear likely to both act via the GLP-1 receptor for at least some
functions. Therefore, analysis of peptide binding at the GLP-1
receptor may give insight into biological function.
Determination of the roles of specific functional groups and
structural properties of Oxmmay provide insight into its mech-
anism of action (15). Furthermore, for peptides with potential
therapeutic applications, clinical use is frequently limitedby their
short duration of action and the consequent need for repeated
administration. Rational modifications of peptide sequence or
secondary structure may enhance bioactivity and/or half-life (16).
The Oxm amino terminus may be involved in receptor bind-
ing and activation. Proglucagon-derived peptides are broken
downat leastpartlyby the enzymedipeptyl peptidase IV (DPPIV)
at the amino terminus (17–19), and rational changes to this part
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of the molecule may modulate susceptibility to DPPIV degrada-
tion (20–23). The midsection of Oxm may also be a target for
degradative enzymes such as the ectopeptidases (24) and neutral
endopeptidase 24.11 (NEP) (24, 25). Proglucagon-derived pep-
tides adopt -helical conformations in environments resembling
the cell membrane (26). Evidence suggests that this helix may be
required for receptor binding (27–29). Oxm differs from gluca-
gon by an eight-amino acid sequence at the carboxy terminus.
Although Oxm binds the glucagon receptor with an affinity 10-
to50-fold lower thanglucagon (30, 31), bothOxmandglucagon
can bind and activate the GLP-1 receptor, though with lower
affinity than GLP-1 (5, 32). Oxm is 10–20 times more potent
than glucagon at inhibiting stimulated gastric acid secretion in
the rat, suggesting a role for the octapeptide extension in medi-
ating this biological action (1). The octapeptide (also known as
spacer peptide II) contains the minimal fragment necessary to
inhibit acid secretion, albeit with a 100-fold reduced potency
compared with full-lengthOxm (2), and, thus, may have a phys-
iological role. Its role in food intake is less clear.
Wehave designed a series ofOxmanalogswithmodifications
to specific regions of the peptide as tools to investigate the effects
of these regions on actions in vivo and in vitro. We have inves-
tigated their binding affinity for the GLP-1 receptor and their
effect on food intake. These studies provide insights into the
structure-function relationships of the Oxm molecule. The re-
sults have aided the development of an Oxm analog with en-
hanced bioactivity for exogenous administration and suggest
that Oxm analogs may have utility as antiobesity agents.
Materials and Methods
Peptides
Peptides were obtained from Advanced Biotechnology Services,
Imperial College London (London, UK) and BioMol International LP
(Exeter, UK). Peptides were synthesized, purified, and analyzed using
established protocols (33–35). Synthesis and purification used auto-
mated Fluorenyl-Methoxy-Carbonyl solid phase peptide synthesis
(Fmoc SPSS). Peptides were synthesized on TentaGel resins, derivatized
with one of a number of cleavable linkers, using an Fmoc/t-butyl-based
solid-phase synthesis strategy. Temporary N-amino group protection
was afforded by the Fmoc-group, with t-butyl ethers being used for
protection of tyrosine, serine, and threonine hydroxyl side chains,
whereas t-butyl esters protected the side chains of aspartic and glutamic
acid residues. Histidine and lysine side chains were protected as their N-
andN-Bocderivatives, respectively, cysteine as its S-trityl derivative, and
arginine guanidine moiety as its Pbf derivative.
Rational peptide modifications can be used to influence the duration
of peptide activity in vivo. For example, elongating a peptide chain can
reduce susceptibility to degradation and clearance (25, 28), and addition
of an acyl side chain can encourage a peptide to bind plasma proteins,
thus reducing breakdown by endopeptidases and impeding metabolic
clearance by the kidney (36). Where N-acylation of lysine was required,
orthogonal protectionwas afforded by the incorporation of 1-(4,4-dimeth-
yl-2,6-dioxocyclohexylidene)3-methyl-butyl lysine (Lys(ivDde)), which
was deprotected on solid phase using 2% hydrazine in dimethylformalde-
hyde. Acylationwas performed using diisopropylcarbodiimide/1-hydroxy-
benzotriazole hydrate. Upon completion of the synthesis, peptides were
cleavedfromthesolidsupport,withremovalofsidechainprotectinggroups,
by treatment with aqueous trifluoroacetic acid (TFA) containing triisobu-
tylsilane as a scavenger. After removal of TFA and scavengers by evapora-
tion and trituration, peptide purification was performed by reversed-phase
preparative HPLC, followed by lyophilization. The purified product was
subsequently analyzed by reverse-phase HPLC and by mass spectrometry.
The sequences of all peptide analogs used are shown in Fig. 1.
Acute feeding studies in mice
C57BL/6 mice (20–25 g; Harlan, Loughborough, UK) were singly
housed, and maintained under controlled conditions of temperature
(21–23 C) and light (lights on at 0700 h, lights off at 1900 h) with ad
libitum access to RM1 diet (Special Diet Services,Witham, UK) (37). All
animal procedures undertaken were approved by the British Home Of-
fice Animals (Scientific Procedures) Act 1986 (Project License 70/5516).
Animalswere acclimatized to laboratory conditions for at least 1wk and
handled daily before the first study, during which time they received two
injections of saline to minimize stress on the study days. Intraperitoneal
and sc injections were administered via a 1-ml syringe with a 28-gauge
needle (maximum injectionvolume0.2ml). For each study, animalswere
fasted from1600 h the preceding day and injected in the early light phase
(0900–1000 h). All peptides were dissolved in 0.9% saline, and 0.9%
saline was administered as a control injection. After injection, animals
were returned to their home cages containing a preweighed amount of
food that was reweighed at 1, 2, 4, 8, and 24 h after injection.
Receptor binding assay
GLP-1 receptor binding study
Plasma membranes from male Wistar rat lung tissue, known to be
rich in GLP-1 receptors, were prepared and binding assays performed as
previously described (4, 38). Rats were killed, lungs removed, andmem-
branes prepared by homogenization and differential centrifugation.
Membranes (200 g) were incubated for 90 min in silanized polypro-
pylene tubes together with [125I]Ex-4 [500 Bq (100 pM)] and unlabeled
competingpeptides (as specified), at 4C inbindingbuffer [50mMHEPES
(pH 7.4), 1 mM MgCl2, 0.1% BSA and protease inhibitors (0.2 mM
phenylmethylsulfonylfluoride; Sigma-AldrichCorp., St. Louis,MO), 0.1
mM Diprotin A (Sigma-Aldrich), and 10 M phosphoramidon (Sigma-
Aldrich)] in a final assay volume of 0.5 ml. Peptides were iodinated as
previously described (39) using 125I from GE Healthcare Life Sciences
(Amersham, Bucks, UK). Pelleted membranes were washed with assay
buffer (0.5 ml, ice cold) and the membranes centrifuged (15,874  g, 2
min, 4 C) as described to separate bound and free label. Bound radio-
activity wasmeasured using a -counter. Specific bindingwas calculated
as the difference between the amount of [125I]Ex-4 bound in the absence
(total binding) and presence of 5 M unlabeled competing peptide (non-
saturable binding). All curves were performed with points in triplicate.
IC50 values were calculated using the Prism 4 program (GraphPad Soft-
ware Inc., San Diego, CA).
Glucagon receptor binding assay
Membranes were prepared as described (38) using the same method as
thatused in theGLP-1Rbindingassayexcept that liverwasusedas the tissue
source. Binding assays were completed as for GLP-1r binding except that
100 ng membrane was used with [125I]glucagon [500 Bq (100 pM)] label.
Degradation assays
DPPIV protease assay
Digest buffer [100mMTris-HCl (pH 8)] containing 15Mpeptide and
1 g porcine kidney DPPIV (Sigma-Aldrich) was incubated at 37 C. The
reaction was terminated at the specified time point by adding 10 l 10%
TFA, followedbyreverse-phaseHPLConaGeminiC18column(Phenome-
nex, Macclesfield, UK). The column was eluted with a linear gradient of
27–31% AcN over 50 min at 1 ml/min. Peptides and their degradation
products were monitored by their absorbance at 214 nm. Percent degrada-
tion was quantified by integration of peak areas related to undigested pep-
tide peaks and corrected for degradation in the absence of enzyme.
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Neutral endopeptidase (neprilysin) protease assay
The neprilysin protease assay was performed as described previously,
but usingdigest buffer 50mMTris-HCl, 50mMNaCl (pH7.5),with200ng
recombinanthumanneprilysin-2(R&DSystems,BadNauheim,Germany).
The incubatedsampleswere runandanalyzedasdescribed,butwitha linear
gradient of AcN in 0.05% TFA (15–60% AcN over 30 min).
Conditioned taste avoidance (CTA)
Animals, diet, peptides, and chemicals were all as described in the pre-
ceding sections. Lithium chloride (127 mg/kg ip) was used as a positive
control (40, 41). Fluid was given in specially designed bottles comprising a
10-ml pipette (Bibby Sterilin Ltd., Staffs, UK), nondrip sipper from 50 ml
mouse feeder bottles (Classic Pet Products, Caldex Ltd., Halifax, UK), and
Parafilm cap (American National Can Group Inc., Chicago, IL), with sep-
arate sets of bottles for water and novel flavor (sweetened Kool-Aid; Kraft
Foods Co., Northfield, IL). Based on an established protocol using a single-
bottle method (40), mice were acclimatized and trained to drink their full
fluidrequirementduringa1-hperiodeachday.Oncestabilized,duringatest
week,ond1and3,1haccess toanovel flavorwaspairedwithanip injection
of saline or peptide. On d 5 (test day), the mice had access to the flavor for
1 h, and fluid intake was measured.
Statistical analysis
Statistical advice was obtained from the Imperial College Statistical
Advisory Service (Imperial College London). Data are shown as mean
and SEM. Food intake study data were analyzed by ANOVA with
Bonferroni’s post hoc test (Prism 4). In all cases P 0.05was considered
statistically significant.
Results
The effect of Oxm on food intake in mice
To establish the dose of Oxm required to cause a robust re-
duction in food intake after ip administration, the effect of Oxm
on food intake in C57BL/6 mice was examined (n  8–10 per
group). Food intake in the first hour was inhibited by doses of
1400 nmol/kg Oxm and above [food intake 0–1 h (g): saline
1.23  0.05, Oxm 800 nmol/kg 1.22  0.9, 1400 nmol/kg
0.95 0.07, 2200 nmol/kg 0.76 0.12, 3800 nmol/kg 0.35
0.04; P  0.05 for 1400 nmol/kg Oxm and above vs. saline].
There was no effect of Oxm on food intake in any group by 24 h
(data not shown).Repeated experiments (n3, data not shown)
showed that the dose ofOxmneeded to reliably reduce food intake
by 25–40% compared with saline control was 1400 nmol/kg.
Effect of DPPIV on the amino terminus of Oxm
Oxm degradation in vitro
After incubation of Oxm with DPPIV for 2 h, no HPLC peak
corresponding to the original peptidewasdetected.The additionof
the specific DPPIV inhibitor Diprotin A to the reaction (42, 43)
completely preventedOxmdegradation (data not shown). The ob-
served degradation can be compared with that seen with ex-
endin-4 as a negative control, GLP-1 and glucagon as compar-
residue position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42
Oxm His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr Lys Arg Asn Arg Asn Asn Ile Ala
Glucagon His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr
GLP-1 His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg
Exendin-4 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser NH2
DHis1-Oxm DHis Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr Lys Arg Asn Arg Asn Asn Ile Ala
Ala2-Oxm His Ala Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr Lys Arg Asn Arg Asn Asn Ile Ala
DHis1-Ala2-Oxm DHis Ala Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr Lys Arg Asn Arg Asn Asn Ile Ala
Oxm(ex15-18) His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Glu Glu Glu Ala Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr Lys Arg Asn Arg Asn Asn Ile Ala
Oxm(ex15-21) His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Glu Glu Glu Ala Val Arg Leu Phe Val Gln Trp Leu Met Asn Thr Lys Arg Asn Arg Asn Asn Ile Ala
Oxm(ex15-23) His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Gln Trp Leu Met Asn Thr Lys Arg Asn Arg Asn Asn Ile Ala
Oxm(ex15-24) His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Met Asn Thr Lys Arg Asn Arg Asn Asn Ile Ala
Oxm(ex27-33) His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Lys Asn Gly Gly Pro Ser Ser Asn Asn Ile Ala
Oxm(ex29-33) His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Gly Gly Pro Ser Ser Asn Asn Ile Ala
Oxm(ex30-33) His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr Gly Pro Ser Ser Asn Asn Ile Ala
Oxm(ex27-30) His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Lys Asn Gly Gly Arg Asn Arg Asn Asn Ile Ala
Oxm19-37 Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr Lys Arg Asn Arg Asn Asn Ile Ala
Oxm30-37 Lys Arg Asn Arg Asn Asn Ile Ala
Oxm-Ala38 His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr Lys Arg Asn Arg Asn Asn Ile Ala Ala
Oxm-Ala38,39 His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr Lys Arg Asn Arg Asn Asn Ile Ala Ala Ala
Oxm-Ala38-42 His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr Lys Arg Asn Arg Asn Asn Ile Ala Ala Ala Ala Ala Ala
Oxm-Lys38-Laur His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr Lys Arg Asn Arg Asn Asn Ile Ala Lys LAUROYL
Oxm-Lys38-Palm His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr Lys Arg Asn Arg Asn Asn Ile Ala Lys PALMITOYL
Oxm-Ala38,39-Lys40Laur His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr Lys Arg Asn Arg Asn Asn Ile Ala Ala Ala Lys LAUROYL
Oxm-Ala38,39-Lys40Palm His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr Lys Arg Asn Arg Asn Asn Ile Ala Ala Ala Lys PALMITOYL
DHis1-Ala2-Oxm(ex15-23) DHis Ala Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Gln Trp Lys Asn Gly Gly Pro Ser Ser Arg Asn Asn Ile Ala Ala Ala Lys LAUROYL
(ex27-33)-Ala38,39-Lys40-
Lauroyl
Key
D-amino acid Change to residue 2 Exendin-like sequence Lys residue for acylation Alanine chain insertion Acyl side chain
FIG. 1. Peptide sequences for analogs used in studies.
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ators, and a degradation-prone modified Oxm (DHis1-Ala2-
Oxm) as positive control (supplemental Fig. 1S, which is
published as supplemental data onTheEndocrine Society’s Jour-
nals Online web site at http://endo.endojournals.org). After in-
cubation of Oxm with DPPIV, mass spectroscopy was used to
determine that the mass of the resulting fragment was in accord
with that of Oxm3-37.
Oxm degradation in vivo
Atotal of 2700nmol/kg ipOxm (ahighbut notmaximal dose
for food intake inhibition) was administered alone or in con-
junction with sc 75 mg/kg valine pyrrolidide (a DPPIV inhibitor
obtained as a kind gift from Novo Nordisk, Crawley, UK) (44),
and effects on food intake in mice were examined. Oxm alone
reduced food intake for the first hour after injection. There was
no effect of DPPIV inhibitor alone on food intake. Coadminis-
tration of DPPIV inhibitor with Oxm enhanced the reduction in
food intake for 1 h after injection (Fig. 2), with no effects during
later time periods (data not shown).
The effect of modifications to the amino terminus of Oxm
on receptor binding and DPPIV degradation in vitro
Amino terminusmodifications affect susceptibility of progluca-
gon-derived peptides and related peptides to degradation (2, 45).
Oxm analogs were synthesized using similar principles to investi-
gate effects on receptor binding and breakdown in vitro byDPPIV.
Some changes reduced receptor binding affinity (Table 1), but sev-
eral also inhibited DPPIV degradation in vitro (Table 2).
The effect of modifications to the amino terminus of Oxm
on bioactivity in vivo
PeptideanalogsDHis-Oxm,Ala2-Oxm,andDHis1-Ala2-Oxm
(receptor binding and degradation shown in Tables 1 and 2) were
administered to mice ip at 2700 nmol/kg, with native Oxm as a
comparator (n 9–10 per group). In the first hour after injection,
Oxmreduced food intake, andDHis1-Oxmreduced food intake to
a similar degree. Ala2-Oxmwas less potent thanOxm and did not
significantlyreducefoodintakecomparedwithsaline.DHis1-Ala2-
Oxm reduced food intake similarly to Oxm in the first hour [food
intake 0–1 h (g) after saline 1.19 0.06, Oxm 0.41 0.06, P
0.001 vs. saline, D-His-Oxm 0.42  0.11, P  0.001 vs. saline,
Ala2-Oxm0.830.05,P0.001vs. salineandP0.01vs.Oxm,
and DHis1-Ala2-Oxm 0.27 0.03, P 0.001 vs. saline]. DHis1-
Ala2-Oxm had a prolonged action, with a greater reduction in
food intake than saline and Oxm-injected animals at 0–2 h
[food intake 0–2 h (g) after saline 1.83  0.09, Oxm 1.29 
0.07, P 0.05 vs. saline, DHis1-Ala2-Oxm 0.47 0.03, P
0.01 vs. saline and P  0.01 vs. Oxm].
Effect of DHis1-Ala2-Oxm on food intake
The dose-response effect of DHis1-Ala2-oxm on food intake
in mice was investigated, using Oxm as comparator and looking
at food intake over the first hour of feeding (n  8 per group).
Oxm 1400 nmol/kg reduced 0–1 h food intake. DHis1-Ala2-
oxm significantly reduced food intake in the first hour at doses
of 500, 1000, and 2000 nmol/kg, and, thus, was more potent
thannativeOxm[food intake0–1h (g): saline 1.010.05,Oxm
1400 nmol/kg 0.60  0.11, DHis1-Ala2-oxm 250 nmol/kg
0.84  0.06, 500 nmol/kg 0.62  0.11, 1000 nmol/kg 0.35 
0.10, 2000 nmol/kg 0.16 0.05; P 0.05 for 500, P 0.01 for
1000 and 2000 nmol/kg DHis1-Ala2-oxm vs. saline].
Effects of alterations to the midsection of Oxm on
receptor binding and endopeptidase degradation
Effects of substitution of short amino acid sequences in the
midsection of Oxm on receptor binding, endopeptidase
degradation, and bioactivity
The GLP-1 receptor agonist exendin-4 has a greater affinity
for the GLP-1 receptor than Oxm or GLP-1 (Table 1) and is less
susceptible to degradation by NEP than Oxm (46) (Table 2 and
supplemental Fig. 2S). Both Oxm and exendin-4 are thought to
have an -helix structure. Oxm analogs were produced with
putative degradation-resistant amino acid sequences from ex-
endin-4 in the midsection: Oxm(ex15-18), Oxm(ex15-21),
Oxm(ex15-23), and Oxm(ex15-24) (Fig. 1).
Insertion of a short exendin-4 sequence (ex15-18) slightly
reduced affinity for the GLP-1 receptor, but longer sequence
inserts (ex15-21) to (ex15-24) increased affinity for the GLP-1
receptor by approximately 10-fold (Table 1). Degradation of the
peptides with the midsection inserts by NEP was reduced com-
pared with native Oxm, with Oxm(ex15-23) the most degrada-
tion resistant of the group (Table 2).
The effects of these peptide analogs on food intake were as-
sessed in vivo. Oxm 2700 nmol/kg reduced food intake signifi-
cantly in the first hour, whereas the Oxm analogs had a more
prolonged effect. The duration of action reflected the receptor
binding data, by the 8- to 24-h interval, only theOxm(ex15-23),
whichhad thegreatest affinity for theGLP-1, causeda significant
reduction in food intake compared with saline (Fig. 3).
Effects of substituting short amino acid sequences in the
midsection/octapeptide junction of Oxm on receptor
binding, endopeptidase breakdown, and bioactivity
To investigate the role of the terminal octapeptide, Oxm
analogs were produced with putative degradation-resistant
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FIG. 2. Effects in mice of valine pyrrolidide (Val-Pyr) 75 mg/kg sc on the
inhibition of food intake over 1 h resulting from the administration of Oxm 2700
nmol/kg ip (n  12 per group). ***, P  0.001 compared with saline (sal) or
comparison between groups indicated.
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amino acid sequences encroaching on the terminal octapep-
tide: Oxm(ex27-33), Oxm(ex29-33), Oxm(ex30-33), and
Oxm(ex27-30) (Fig. 1). The modified peptides had greater
affinity for the GLP-1 receptor than native Oxm, except
(ex30-33), which showed reduced receptor binding (Table 1).
Incubation of Oxm with NEP resulted in degradation of the
peptide (Table 2) with multiple degradation products (sup-
plemental Fig. 2S). The analogs were more resistant to NEP
degradation, with the highest protection from degradation
observed with Oxm(ex27-33) (Table 2).
The effect of two representative peptides on food intake in
mice was studied. Oxm 2700 nmol/kg reduced food intake sig-
nificantly in the first hour. Oxm(ex30-33) had a similar effect.
Oxm(ex27-33)was significantlymore bioactive thanOxm in the
first hour (P 0.001), and the effects on food intake lasted until
the 4- to 8-h interval (Fig. 4).
The role of the carboxy terminus of Oxm in the
bioactivity of Oxm on food intake in vivo
To investigate whether the terminal octapeptide is necessary
for the effects of Oxm on food intake, Oxm and glucagon were
compared.Oxmhad greater affinity for theGLP-1 receptor than
glucagon, which did not show specific binding at the highest
doses tested (IC50 33.1 for Oxm and 10,000 for glucagon)
(Table 1). At the rat glucagon receptor, Oxm bound with mark-
edly loweraffinity thanglucagon[glucagonIC501.1nM(0.84–1.4),
Oxm IC50 18.6 nM (14–24)], whereas GLP-1 and exendin-4
showed no binding (IC5010,000).When the effects of Oxm and
glucagon on food intake in mice were compared, a dose of 1400
nmol/kgOxm inhibited food intake,whereas the effect of glucagon
wasnot statistically significant [food intake0–1h (g): saline0.91
0.07,Oxm1400nmol/kg 0.200.05 (P0.001), glucagon1400
nmol/kg 0.60 0.10 (P 0.05 vs. saline and P 0.01 vs. Oxm)].
TABLE 1. Receptor binding affinity for Oxm and analogs for the GLP-1 receptor
Peptide/analog Mean IC50 (nM) 95% Confidence interval
Natural sequence peptides
Oxm (shown for comparison) 33.1 27.2–49.0
Glucagon 10,000 Not applicable
GLP-1 (shown for comparison) 0.34 0.27–0.41
Exendin-4 (shown for comparison) 0.27 0.21–0.35
N terminus modifications
Des-His-Oxm 10,000 Not applicable
Acetyl-Oxm 10,000 Not applicable
DHis-Oxm 1,064 792–1,336
Ala2-Oxm 28.1 21.8–35.9
DHis1-Ala2-Oxm 544 398–744
DHis1-Val2-Oxm 5,000 Not applicable
DHis1-Ala2-Glu3-Oxm 624 393–983
DHis1-Ser2-Glu3-Oxm 972 323–2,393
His1-Gly2-Gln3-Oxm 367 224–602
DHis1-Gly2-Gln3-Oxm 3,540 2,755–4,355
Midsection modifications
Oxm(ex15-18) 59.0 34.0–99.0
Oxm(ex15-21) 4.0 3.0–5.3
Oxm(ex15-23) 2.2 1.4–3.5
Oxm(ex15-24) 4.6 3.0–7.1
Oxm(ex30-33) 199 128–309
Oxm(ex29-33) 4.8 2.3–10.1
Oxm(ex27-33) 9.6 5.5–16.8
Oxm(ex27-30) 10.3 6.7–16.3
Carboxy terminus fragments
Oxm19-37 10,000 Not applicable
Oxm30-37 10,000 Not applicable
Carboxy terminus modifications
Oxm-Ala38 194 129–301
Oxm-Ala38,39 20.8 16.0–26.7
Oxm-Ala38-42 39.0 25.0–58.0
Oxm-Lys38-Octanoyl 322 91.0–738
Oxm-Lys38-Lauroyl 476 178–1,200
Oxm-Lys38-Palmitoyl 538 255–1,100
Oxm-Ala38,39-Lys40-Lauroyl 36.0 21.5–60.3
Oxm-Ala38,39-Lys40-Palmitoyl 25.7 16.5–40.0
Combined N terminus, midsection, and carboxy
terminus modifications
DHis1-Ala2-Oxm(ex15–23)(ex27–33)-
Ala38,39-Lys40-Lauroyl
0.79 0.59–1.0
IC50 value calculated from a minimum of three separate experiments, each concentration tested in triplicate in each experiment.
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Because the minimally active fragment of Oxm for gastric
acid secretion has been reported to lie in the carboxy terminus,
the effects ofOxm carboxy-terminal fragments (Oxm19-37 and
Oxm30-37) on food intakewere evaluated.NeitherOxm19-37
norOxm30-37displayed specific affinity for theGLP-1 receptor
at the highest doses tested (IC50  10,000 nM) (Table 1). Frag-
ments (Oxm19-37 andOxm30–37; Fig. 1) were administered ip
tomice.Oxm1400nmol/kg reduced food intake in the first hour
after injection, but the fragments tested did not reduce food in-
take at this dose or at 10,000 nmol/kg (data not shown).
The carboxy terminus of Oxm may be susceptible to degra-
dation. Complex additions to peptide sequences can reduce
breakdown butmay interferewith secondary struc-
ture and receptor binding. Oxm analogs were syn-
thesized with the addition of alanine residues at the
C terminal to investigate the effects of C-terminal
elongationon food intake.The effect of thepeptides
Oxm-Ala38, Oxm-Ala38,39, and Oxm-Ala38-42
on receptor binding and food intake were compared
with native Oxm. Oxm-Ala38 had lower binding to
the GLP-1 receptor than Oxm, but Oxm-Ala38,39
had slightly greater affinity for the GLP-1 receptor.
The affinity of Oxm and Oxm-Ala38-42 for the
GLP-1 receptor was comparable (Table 1). Degrada-
tion of the extended peptides by NEP in vitro was
reduced comparedwith that of nativeOxm(Table 2).
When administered in vivo to mice, all three elon-
gated peptides had a similar effect on food intake to
nativeOxm.Oxm-Ala38,39hada slightly greater an-
orectic effect than Oxm, but this difference was not
statistically significant [food intake 0–1 h (g) after sa-
line 0.91  0.05, Oxm 0.53  0.13, P  0.05 vs.
saline, Oxm-Ala38 0.52 0.11, P 0.05 vs. saline,
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FIG. 3. Effects on 24 h food intake, after an overnight fast in mice, after ip administration of
human Oxm 2700 nmol/kg, or Oxm analog peptides with sequence replacements with exendin
sequence Oxm(ex15-18), Oxm(ex15-21), Oxm(ex 15-23), and Oxm(ex15-24) all at 2700 nmol/kg
(n  6–8 per group). ***, P  0.001 compared with saline.
TABLE 2. Effect of rational modifications of the Oxm N terminal on DPPIV-induced peptide degradation and of the Oxm
midsection and carboxy terminus on NEP-induced peptide degradation in vitro
Peptide % Degradation with DPPIV at 2 h % Degradation with NEP
Natural sequence peptides
Oxm 100 (40% at 30 min) 77
GLP-1 100 100
Exendin-4 0 0
Glucagon 100 81
N terminus modifications
Des-His-Oxm 0 Not tested
Acetyl-Oxm 0 Not tested
DHis-Oxm 0 Not tested
Ala2-Oxm 100 (95% at 30 min) 70
DHis1-Ala2-Oxm 0 Not tested
DHis1-Val2-Oxm 0 Not tested
DHis1-Ala2-Glu3-Oxm 0 Not tested
DHis1-Ser2-Glu3-Oxm 0 Not tested
His1-Gly2-Gln3-Oxm 51 (19% at 30 min) Not tested
DHis1-Gly2-Gln3-Oxm 0 Not tested
Midsection modifications
Oxm(ex15-18) Not tested 38
Oxm(ex15-21) Not tested 39
Oxm(ex15-23) Not tested 0
Oxm(ex15-24) Not tested 6
Oxm(ex30-33) Not tested 8
Oxm(ex29-33) Not tested 4
Oxm(ex27-33) Not tested 0
Oxm(ex27-30) Not tested 12
Carboxy terminus modifications
Oxm-Ala38 Not tested 41
Oxm-Ala38,39 Not tested 24
Oxm-Ala38-42 Not tested 37
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Oxm-Ala38,39 0.24 0.04, P 0.001 vs. saline, Oxm-Ala38-42
0.60  0.07, P  0.05 vs. saline]. Food intake for all groups re-
turned to baseline after 1 h after injection (data not shown).
The effect of altered protein binding on bioactivity of Oxm
Additionofacylgroups toapeptidecan increasepeptidebinding
to albumin, and impair degradation and clearance (47, 48). Oxm
analogs were synthesized with the C terminus extended by a lysine
residue (Lys 38) to which an acyl group was attached, comprising
eight, 12, or 16 residues. These peptides had reduced binding to the
GLP-1 receptor (Table 1). When administered at 1400 nmol/kg in
vivo (n8–10per group), they had less effect on food intake in the
firsthourafteradministrationthanOxmatthesamedose,withonly
native Oxm and Oxm-Lys38 showing statistically significant re-
ductions in food intake comparedwith saline control
(P 0.05). The peptides did not affect food intake at
later time points (data not shown).
With theaimof reducingacyl-group interference
with receptorbinding, further carboxy-terminal ex-
tended analogs were developed with the acyl side
chain attached further from the putative -helix re-
gion. Oxm-Ala38,39-Lys40-Lauroyl and Oxm-
Ala38,39-Lys40-Palmitoyl bound to the GLP-1 re-
ceptor with affinities similar to that of native Oxm
(Table 1).When administered tomice in vivo, these
peptides reduced food intake in the first hour after
administration and had a significantly more inhib-
itory effect than Oxm for up to 4 h after adminis-
tration (Fig. 5), with a trend to correction in the 4-
to 8-h period. There were no significant effects in
the 8- to 24-h period (data not shown).
The contribution of peptide domains of Oxm
to nausea and CTA
As discussed previously, in repeated experi-
ments, Oxm 1400 nmol/kg caused a 30–40% re-
duction in food intake in mice in the first hour after injection,
compared with saline control. Food intake studies were per-
formed to establish dose-response curves for exendin-4 and for
Oxm analogs with alterations in each of three domains [DHis1-
Ala2-Oxm, Oxm(ex15–24) and Oxm(ex27–33)] (supplemental
Fig. 3S). These studies were used to determine a dose predicted
to reduce food intake by 30–40% in the first hour after admin-
istration: exendin-4 1 nmol/kg, DHis1-Ala2-Oxm 500 nmol/kg,
Oxm(ex15–24) 7 nmol/kg, and Oxm(ex27–33) 150 nmol/kg.
ACTAstudywas performed to examine the effects of the native
peptides GLP-1, Oxm, and exendin-4 at doses that either reduce
food intake 30–40% at 1 h or by a 3-fold higher dose. Exendin-4
administered at the 3-fold higher dose caused CTA, whereas pep-
tides administered at the lower dose did not (supplemental Fig. 4S).
Peptides were administered at doses 3-fold higher
than those required to reduce food intake at 1 h by
30–40% (n 6–8 per group). The doses adminis-
teredwereOxm4200 nmol/kg, exendin-43 nmol/kg,
DHis1-Ala-Oxm1500nmol/kg,Oxm(ex15-24).The
positive control, lithium chloride, reduced Kool-Aid
intake significantly. Exendin-4 had a trend toward
and Oxm reduced Kool-Aid intake compared with
saline. TheOxmanalogs all reducedKool-Aid intake
compared with saline, with no significant difference
between the Oxm analogs [mean intakes 0–1 h (ml)
1.49  0.06 for saline, 0.05  0.03 for LiCl, P 
0.001 vs. saline, 1.190.2 for exendin-4,P0.1 vs.
saline, 1.03  0.1 ml for Oxm, P  0.05 vs. saline,
0.69 0.2 for DHis1-Ala2-Oxm, P 0.01 vs. saline,
0.960.1 forOxm(ex15–24),P0.05 vs. saline, and
0.38 0.1 for Oxm(ex27–33), P 0.01 vs. saline].
WhentheOxmanalogpeptideswereadministered
at the doses that reduced food intake by 30–40% at
1 h, in a CTA paradigm (n  7–8 per group), there
were no significant effects on Kool-Aid intake. The
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FIG. 4. Effects on food intake for 8 h after an overnight fast in mice, after ip administration of
human Oxm 2700 nmol/kg, or Oxm analog peptides with sequence replacements with exendin
sequence Oxm(ex30-33) and Oxm(ex27-33) all at 2700 nmol/kg (n  9–10 per group). *, P 
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FIG. 5. Effects on food intake for 8 h after an overnight fast in mice, after ip administration of
saline or human Oxm, Oxm-Ala38,39-Lys40-Lauroyl or Oxm-Ala38,39-Lys40-Palmitoyl at 1400
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positive control, lithium chloride, reduced Kool-Aid intake signif-
icantly. None of the other peptides tested significantly reduced
Kool-Aid intake compared with saline [mean intakes 0–1 h (ml)
1.930.13 for saline, 1.130.29 forLiClP0.05vs. saline, and
1.66 0.15 for exendin-4, 1.68 0.11 ml for Oxm, 1.61 0.19
forDHis1-Ala2-Oxm,1.550.13 forOxm(ex15–24), and1.69
0.07 for Oxm(ex27–33): all P 0.05 vs. saline].
The effect of combining modifications to Oxm in a
single analog on binding, degradation, and clearance
AnOxmanalogwas synthesizedwith changes in the different
peptide regions combined in a single molecule (Fig. 1), and the
effects on food intake were examined. The effect of peripheral
administration of 10, 30, 100, and 300 nmol/kg DHis1-Ala2-
oxm(ex15-23)(ex27-33)-Ala38,39-Lys40-Lauroyl on food in-
take was compared with that of Oxm 1400 nmol/kg. Oxm and
all doses of the Oxm analog DHis1-Ala2-oxm(ex15-23)(ex27-
33)-Ala38,39-Lys40-Lauroyl reduced food intake in the first
hour after administration (Fig. 6). A dose of 10 nmol/kg DHis1-
Ala2-oxm(ex15-23)(ex27-33)-Ala38,39-Lys40-Lauroyl re-
duced food intake significantly until 8 h after administration,
anddoses of 100or300nmol/kgwere still effective at 24h.Thus,
a much lower dose of this analog was required to reduce food
intake than would be required of Oxm. The combination of
changes together improved the binding to the GLP-1 receptor
10-fold compared with native Oxm (Table 1). The effects of this
multiplymodified peptide onCTA suggest that itmay have a less
marked effect on CTA than exendin-4 (supplemental Fig. 5S).
Discussion
Modifications to the structure of Oxm generated peptides with
increased binding to the GLP-1 receptor, reduced enzyme deg-
radation, and increased anorectic effects. This increase in bio-
activity appears to reflect an increase in the magnitude of acute
effects and/or an increase in the duration of effect.
The first series of experiments investigated the properties of the
amino terminusofOxm.DPPIV is amembrane-boundectoenzyme
believed important in the biological regulation of peptides, includ-
ingGLP-1.DPPIVcleavesanNH2-terminaldipeptide,particularly,
butnotexclusively, frompeptideswithapenultimateaminoproline
or alanine residue (17).DPPIVhas degraded bothGLP-1 andOxm
in vitro (49), althoughOxmwas less susceptible to degradation by
theenzyme.Weconfirmthat invitro,Oxmandrelatedpeptides can
be degraded by DPPIV. However, exendin-4 is resistant to degra-
dation byDPPIV (Table 2 and supplemental Fig. 1S). As predicted,
Oxm3–37 is the major breakdown product.
UnlikeGLP-1, a role forDPPIV in the in vivo regulationofOxm
hadnotpreviouslybeendemonstrated,althoughOxmisasubstrate
for DPPIV in vitro (49). The greater reduction in food intake after
coadministration ofOxm and aDPPIV inhibitor suggests that DP-
PIV is involved inOxmbreakdown in vivo. The greater food intake
reduction at 1 h after administration is likely to represent a short
extension of the half-life of Oxmwithin this first hour, rather than
an increase in potency. Because DPPIV has strict substrate require-
ments (50), we synthesized analogs likely to have altered suscepti-
bility to DPPIV cleavage (21, 22). Analogs for which in vitro ex-
periments suggested resistance toDPPIV degradation, such asDes-
His-Oxm,DHis1-oxm, andDHis1-Ala2-oxm reduced food intake
invivo, andDHis-1-Ala2-Oxmappeared tohave increasedpotency
and a more prolonged action compared with native Oxm. In con-
trast, the analog Ala-2-Oxm, which in vitro experiments predicted
to be more susceptible to DPPIV degradation, was less effective on
food intake in vivo than Oxm. These data suggest that DPPIV can
influence Oxm breakdown.
In addition to DPPIV, Oxm degradationmay involve endopep-
tidases.Specificmodifications toeither themidsectionor thesection
including the octapeptide of Oxm were able to in-
crease receptor binding affinity. NEP is a membrane-
bound zinc metallopeptidase that cleaves peptides at
the NH2-terminal side of aromatic or hydrophobic
aminoacids.GLP-1 is a substrate forNEP in vivo (24,
25)withsixpotentialNEPcleavagesites.Degradation
ofOxmbyNEP producesmultiple cleavage products
(supplemental Fig. 2S). Exendin-4, which has amuch
longer circulating half-life thanGLP-1, lacksmany of
these cleavage sites (25). Exendin-4 also contains a
nine-amino acid C-terminal sequence reported to im-
prove receptor binding affinity (51). In contrast to the
rapid metabolic clearance of GLP-1, the clearance of
exendin-4 in humans is similar to the glomerular fil-
tration rate (52), suggesting that the kidneys are im-
portant in exendin-4 clearance. Replacement of short
peptide sequences of Oxm by exendin-4 sequence re-
duced degradation byNEP and led to a greater dura-
tionofactionon food intake.Thesemodifiedpeptides
hadgreater potency thanOxmon food intakebut less
than exendin-4 itself. These data suggest that, as in
GLP-1, themidsectionofOxmplaysa role in receptor
binding and endopeptidase degradation. However,
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there are likely to be additional endopeptidases involved in the
breakdown of both GLP-1 and Oxm in vivo in addition to DPPIV
and NEP (53), and relative resistance to these as yet unidentified
factorsmay contribute to the differences in bioactivity observed
between the peptides in vivo.
Elongation of the Oxm molecule by two amino acids did not
impair receptor binding and increased bioactivity. Addition of fur-
ther residues did not further increase bioactivity. This could be due
to steric interference with receptor binding. The more sustained
actionof acylatedOxm is in accordwithpossible reduction in renal
clearance as proposed for acylated GLP-1 analogs (36). Oxm an-
alogs with acyl groups on Lys38 showed reduced affinity for
the GLP-1 receptor and caused only nonsignificant reductions
in food intake. However, analogs of Oxm with acyl groups at-
tached to Lys40 retained the receptor affinity of the native mol-
ecule, and the duration of action of the peptide on food intake
was increased.Thissuggests thatacylationof thepeptidecanincrease
the duration of action ofOxm in vivobut that the acyl groupmust be
carefully positioned not to compromise receptor binding affinity.
The role of the carboxy terminus octapeptide ofOxmwas stud-
iedby investigating the effects ofC terminusOxmfragments andof
glucagononGLP-1 receptor binding andon food intake.Glucagon
givenat the samedoseasOxmdidnothavea statistically significant
effect on food intake inmice. The fragments of Oxm tested had no
specific affinity for the GLP-1 receptor and did not affect food in-
take even at very high doses. Thus, glucagon and the C-terminal
octapeptide of Oxm contribute to GLP-1 receptor binding and ef-
fects on food intake, but independently are insufficient to cause
these effects. It is interesting that C-terminal fragments have previ-
ously been shown to have biological activity of other types such as
gastric acid secretion (54, 55), and the discrepancy between this
effect and effects on feeding is worthy of further investigation.
Our results did not demonstrate any effect of Oxm or mod-
ified analogs of Oxm when given at similar doses to those that
reduce food intake by 30–40%. When administered at higher
doses, all were capable of producing CTA; the specific modifi-
cations did not have differential effects. This is in accordwith the
suggestion that nausea (for which CTA is a surrogate) may lie at
one endof the spectrumofnormal satiationand, therefore, reflect
the propensity of a substance to inhibit food intake (56). Further
studies investigating the effects on CTA of Oxm analogs that are
activeat lowdoses toreduce food intakeover long timeperiodsmay
determine whether a smaller acute and longer chronic reduction in
food intake may be associated with reduced avoidance.
Finally, studies using an analog ofOxm incorporating several
domain changes and modifications suggested that these changes
can have an additive effect on biological activity in vivo. Effects
of this peptide with multiple modifications on CTA at different
doses, compared with a high dose of exendin-4, suggest that the
modified peptide may have a slightly less marked effect on CTA
than exendin-4. However, these results are preliminary and as-
sume a linear relationship between dose and avoidance, not
proven for all appetite-regulating peptides (57).
Thus, these studies have provided information regarding
structure-function relationships for particular domains of Oxm.
In addition, Oxm has been proposed as a potential therapy for
obesity (11). UsingOxm analogs could reduce the amount of pep-
tide requiredand/or the frequencyofadministrationwhile retaining
the appetite and weight-reducing qualities of the peptide. Future
studieswill examine the effects of acute and chronic administration
of Oxm analogs on feeding, body weight, insulin secretion, and
energy expenditure. Further work is required to determine the po-
tential utility of Oxm analogs as treatments for obesity.
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